Text Size

Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00158873
First received: September 8, 2005
Last updated: October 15, 2008
Last verified: October 2008
History of Changes
  Purpose

The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU, difference in extubation time and use of concomitant sedative agents.


Condition Intervention Phase
Sedation
 Drug: midazolam
Drug: lorazepam
Drug: fentanyl
Drug: morphine
Drug: remifentanil
Drug: propofol
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU Subjects Requiring Short-Term Mechanical Ventilation With Analgesia and Sedation

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Health Outcome: Duration of time on mechanical ventilation

Secondary Outcome Measures:
  • Health Outcome: length of stay in ICU, in hospital, requirement of opioid and sedative agents, duration of extubation process. Safety: haemodynamics and adverse events. Efficacy: sedation and pain scores

Estimated Enrollment: 224
Study Start Date: September 2004
Intervention Details:
    Drug: midazolam Drug: lorazepam Drug: fentanyl Drug: morphine Drug: remifentanil Drug: propofol
    Other Names:
    • midazolam
    • lorazepam
    • fentanyl
    • morphine
    • remifentanil
    • propofol
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ICU patients with an expected duration of mechanical ventilation for 2 to 3 days and requiring analgesia and sedation.

Exclusion criteria:

  • ICU patients resuscitated in the previous 24 hours, neurotrauma or expecting major surgery, not likely to survive of with limit care status.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00158873

Locations
Netherlands
GSK Investigational Site
Alkmaar, Netherlands, 1815 JD
GSK Investigational Site
Amsterdam, Netherlands, 1081 HV
GSK Investigational Site
Apeldoorn, Netherlands, 7334 DZ
GSK Investigational Site
Den Bosch, Netherlands, 5211 RW
GSK Investigational Site
Den Haag, Netherlands, 2512 VA
GSK Investigational Site
Dordrecht, Netherlands, 3318 AT
GSK Investigational Site
EDE, Netherlands, 6716 RP
GSK Investigational Site
Eindhoven, Netherlands, 5623 EJ
GSK Investigational Site
Haarlem, Netherlands, 2035 RC
GSK Investigational Site
Helmond, Netherlands, 5707 HA
GSK Investigational Site
Hengelo, Netherlands, 7555 DL
GSK Investigational Site
Rotterdam, Netherlands, 3015 GJ
GSK Investigational Site
Tiel, Netherlands, 4002 WP
GSK Investigational Site
Venlo, Netherlands, 5912 BL
GSK Investigational Site
Zwolle, Netherlands, 8011 JW
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00158873     History of Changes
Other Study ID Numbers: 101653
Study First Received: September 8, 2005
Last Updated: October 15, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by GlaxoSmithKline:
ICU mechanical ventilation analgesia sedation

Additional relevant MeSH terms:
Midazolam
Fentanyl
Lorazepam
Propofol
Remifentanil
Morphine
Adjuvants, Anesthesia
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
 Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Narcotics
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Analgesics, Opioid
Anticonvulsants
Antiemetics

ClinicalTrials.gov processed this record on May 23, 2013